Safety of medications prescribed before and during early pregnancy in a cohort of 81 975 mothers from the UK General Practice Research Database

被引:78
作者
Hardy, Janet R. [1 ]
Leaderer, Brian P. [1 ]
Holford, Theodore R. [1 ]
Hall, Gillian C. [1 ]
Bracken, Michael B. [1 ]
机构
[1] Univ Massachusetts, Sch Med, Div Prevent & Behav Med, Worcester, MA 01655 USA
关键词
cohort studies; pregnancy; pregnancy trimester [first; drug prescriptions; medical record linkage; factual databases;
D O I
10.1002/pds.1269
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 [公共卫生与预防医学]; 120402 [社会医学与卫生事业管理];
摘要
Purpose To demonstrate a linkage methodology for mother and baby automated medical records, and describe frequency, type, and pregnancy risk level of medications prescribed during pregnancy in a GPRD cohort, 1991-1999. Methods We linked records using a two-stage algorithm and selected pairs with >= 7 months prenatal records and >= 2 records in baby's first year of life. Periods of interest were: 90 days prior to a woman's earliest identified pregnancy record (Period I), and this record plus 70 days (Period II, approximate early pregnancy). Medications were classified using the British National Formulary and US Food and Drug Administration Pregnancy Risk Categories. Results We achieved over 80% record linkage and defined a cohort of 81975. Sixty-five percent of mothers had >= 1 prescription during both periods combined. Most frequent medications in Period I were anti-bacterial, contraceptive, topical steroid, and bronchodilator. In Period II, they were folic acid, anti-bacterial, antacid, and gynecological anti-infective. In Period I, 4% were FDA category A (considered safest), 34% B, and 49% C and D combined. By Period II, prescription of category A medications increased (folic acid, iron) while other categories declined. Category X medications, with potential teratogenic risk that outweighs maternal benefit, were prescribed to 5714 (7%) women in Period I, and 501 (0.6%) women in Period II (46% progesterone). Conclusions One in every 164 women received a category X prescription in early pregnancy. The visit when pregnancy is first medically recognized represents an opportunity to review prescribed medications in light of contraindication and/or fetal risk. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:555 / 564
页数:10
相关论文
共 32 条
[1]
Risk classification systems for drug use during pregnancy - Are they a reliable source of information? [J].
Addis, A ;
Sharabi, S ;
Bonati, M .
DRUG SAFETY, 2000, 23 (03) :245-253
[2]
Prescription drug use in pregnancy [J].
Andrade, Susan E. ;
Gurwitz, Jerry H. ;
Davis, Robert L. ;
Chan, K. Arnold ;
Finkelstein, Jonathan A. ;
Fortman, Kris ;
McPhillips, Heather ;
Raebel, Marsha A. ;
Roblin, Douglas ;
Smith, David H. ;
Yood, Marianne Ulcickas ;
Morse, Abraham N. ;
Platt, Richard .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (02) :398-407
[3]
*AUSTR DRUG EV COM, 1989, MED PREGN WORK PART
[4]
Bracken MB, 1984, PERINATAL EPIDEMIOLO, P423
[5]
Postmarketing surveillance and adverse drug reactions - Current perspectives and future needs [J].
Brewer, T ;
Colditz, GA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (09) :824-829
[6]
*BRIT NAT FORM, 2004, BRIT NAT FORM 49 ONL
[7]
Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare [J].
Cooper, WO ;
Hickson, GB ;
Ray, WA .
PAEDIATRIC AND PERINATAL EPIDEMIOLOGY, 2004, 18 (02) :106-111
[8]
Risk of drug-induced congenital defects [J].
De Santis, M ;
Straface, G ;
Carducci, B ;
Cavaliere, AF ;
De Santis, L ;
Lucchese, A ;
Merola, AM ;
Caruso, A .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2004, 117 (01) :10-19
[9]
Review of pregnancy labeling of prescription drugs: Is the current system adequate to inform of risks? [J].
Doering, PL ;
Boothby, LA ;
Cheok, M .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 187 (02) :333-339
[10]
FASS, 1993, CLASS MED PROD US PR